Navigation Links
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Date:9/15/2008

EDP-322 is a First-in-class MRSA-active Bicyclolide, a novel

macrolide-related drug class

WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase 1 study on investigational oral antibiotic EDP-322, a first-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile. The clinical development program for EDP-322 will include the treatment of hospital- and community-acquired gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Preclinically, EDP-322 has demonstrated strong in vitro activity against hospital-acquired MRSA strains resistant to vancomycin, Zyvox(R) (linezolid), and CUBICIN(R) (daptomycin).

"Macrolides have been commonly prescribed to treat community infections for decades due to their convenient oral dosing and favorable safety profile," said Robert Moellering, M.D., a professor of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. "Now with the discovery of a new generation of macrolides having high potency against hospital-acquired pathogens and a distinct resistance profile relative to other hospital antibiotics, there is a tremendous new opportunity to explore their use within not only the community, but the hospital setting as well."

"In our in vitro studies, EDP-322 demonstrated good potency against both hospital- and community-acquired MRSA, even against highly drug-resistant MRSA strains," explained Yat Sun Or, Ph.D., Senior Vice President of Research and Development at Enanta. "The potency of EDP-322 against hospital-acquired MRSA, community-acquired MRSA, and other gram-positive pathogens, combined with the convenience of oral administration, has the potential to uniquely position EDP-322 among marketed MRSA drugs in both the hospital and community settings."

<
'/>"/>
SOURCE Enanta Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
3. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
7. Isis Initiates Clinical Trial of CRP Drug
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
10. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
Breaking Medicine News(10 mins):Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... molecules that are responsible for controlling genes that cause ... Memorial Sloan-Kettering Cancer Center (MSKCC), appears in the January ... inhibit the activity of entire sets of genes associated ... the majority of cancer-related deaths. The new work explains ...
... PRGO ; TASE) today announced that it has ... in Barnsley, Yorkshire,United Kingdom, privately-held Galpharm is a leading ... super,markets, drug stores and pharmacies in the U.K. The ... sales annually and be accretive to earnings,in the first ...
... Court Justice Antonin Scalia, FDA Commissioner Andrew C.,von ... FDLI/FDA,Meeting in Washington, D.C., WASHINGTON, Jan. 9 ... Conference, co-sponsored with the Food and Drug,Administration, will ... and food & drug law & regulation., ...
... Trial Begins this Week in Fort Worth, Texas in an ... Toxins in the Air,Destroying a Town, Hundreds of Residents ... Birth Defects, NEW YORK, Jan. 9 The first ... a railroad tie,factory poisoned residents in the small town of ...
... a quick fix to physical and mental ailments, psychoanalysts ... about the potential benefits and drawbacks of including medication ... The Uses of Medications in Psychoanalysis: What We Know; ... psychoanalyst Glen O. Gabbard, M.D., at the American Psychoanalytic ...
... Extract Released Just in Time for the Holiday ... ... The average American gains 50%,of his yearly weight gain during the Holiday ... overweight., Metabothin ( http://www.metabothin.net ), the herbal weight loss formula,from American ...
Cached Medicine News:Health News:Molecules can block breast cancer's ability to spread 2Health News:Perrigo Acquires UK OTC Store Brand Supplier 2Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 2Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 3Health News:Worse Than Love Canal - A Town Poisoned by Corporate Greed 2Health News:Uses of medications in psychoanalysis 2Health News:Metabothin B56 with Ephedra Extract Now Available 2
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... malleable penile prostheses offer easy-to-use, low-cost options ... These implants are always rigid, but their ... in an erect or concealed position. Designed ... sexual intercourse and to not interfere with ...
... The Alpha I continues to be ... show the Alpha I to have mechanical ... years on first-time implants. ioflex material contributes ... Alpha I. Thats because Bioflex: ,Provides maximum, ...
Medicine Products: